Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets

Author(s):  Kaila Nitin, El-Ries Mohamed, Riga A, Alexander Kenneth S, Dollimore D

Issue:  May/Jun 2003 - Diabetes and Wound Care
View All Articles in Issue

Page(s):  233-239

Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets Page 1
Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets Page 2
Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets Page 3
Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets Page 4
Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets Page 5
Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets Page 6
Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets Page 7

Download in electronic PDF format for $75

Abstract:  The qualification and quantification of dapsone in suspension were developed and shown to be stability indicating by means of a reverse-phase high-performance liquid chromatographic method. The real solubility of dapsone in water was calculated to be 0.208 mg/mL at 25°C. The enthalpy of solution and the entropy of solution were calculated to be -175.6 J/g and -43605.7 J/K/M, respectively. An extemporaneous suspension was formulated from commercially available dapsone tablets, and the chemical stability of dapsone in the suspension was determined by means of accelerated stability testing. The 91-day analytical stability testing study was conducted at 4, 30, 50, 60, and 70°C. The energy of activation for the suspension was determined to be –23288.35 J/K/M. The zero-order rate of degradation for dapsone (k0,25) in suspension at 25°C was found to be 0.040845 day-1. The first-order rate of degradation for dapsone in solution was found to be 0.196370 (mg/mL)(day-1). The shelf life for the suspension was calculated to be 31.67 days at 25°C and 230.76 days under refrigeration at 4°C.

Related Keywords: Dapsone tablets, formulation development of extemporaneous suspension prepared from, Dapsone tablets, stability testing of extemporaneous suspension prepared from

Related Categories: PEER-REVIEWED, STABILITIES, COMPATIBILITIES

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets
Kaila Nitin
, El-Ries Mohamed, Riga A, Alexander Kenneth S, Dollimore D
May/Jun 2003
Pg. 233-239

Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride
Alexander Kenneth S
, Thyangarajapuram N
Sep/Oct 2003
Pg. 389-393

A Pilot Stability Study of Dehydroepiandrosterone Rapid-dissolving Tablets Prepared by Extemporaneous Compounding
Rush Steven D
, Vernak Charlene, Zhao Fang
Jan/Feb 2017
Pg. 83-87

Preparation and Stability Evaluation of Extemporaneous Oral Suspension of Valsartan Using Commercially Available Tablets
Zaid Abdel Naser
, Assali Mohyeddin, Qaddomi Aiman, Ghanem Mashhour, Zaaror Yara Abu
Mar/Apr 2014
Pg. 169-174

Extemporaneous Formulation and Stability Testing of Mexiletine HCl Solution
Alexander Kenneth S
, Kaushik Sarita
Mar/Apr 2004
Pg. 147-152

Stability of Allopurinol Suspension Compounded from Tablets
Alexander Kenneth S
, Davar Nipun, Parker Gordon A
Mar/Apr 1997
Pg. 128-131

Formulation and Stability Evaluation of Extemporaneously Prepared Atenolol Capsules from Crushed Atenolol Tablets
Zaid Abdel Naser
, Malkieh Numan, Kharoaf Maher, Ghoush Abeer Abu, Al-Ramahi Rowa'
Jul/Aug 2012
Pg. 342-346

Dapsone 2 mg/mL in SyrSpend SF pH4 Oral Suspension
Allen Loyd V Jr
Nov/Dec 2017
Pg. 491

Dapsone 2-mg/mL in Oral Mix or Oral Mix SF Suspension
Allen Loyd V Jr
Sep/Oct 2021
Pg. 415

Physicochemical Stability of the Extemporaneous Ibuprofen Oral Suspension in "Wagner" Base
Spennacchio Antonio
, Lopedota Angela, la Forgia Flavia, Fontana Sergio, Franco Massimo, Denora Nunzio
Jan/Feb 2023
Pg. 72-77

Extemporaneous Indomethacin Oral Suspension Prepared from Injectable Ampules for Therapy in Premature Infants and Pediatric Patients
de Lafuente Yanina
, García Mónica Cristina, Jiminez-Kairuz Alvaro
Jul/Aug 2019
Pg. 324-331

Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF pH4
Espana B
, Joseph-Tornabène F, Jaquet Cécile, Perrot S, Prouillac C
Jul/Aug 2020
Pg. 327-336

Formulation and Stability Study of Eslicarbazepine Acetate Oral Suspensions for Extemporaneous Compounding
Zhao Fang
, Dave Vivek S, Mar Mazin Z, Perri Jonathan R
Sep/Oct 2018
Pg. 433-439

Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions
Kabiche Djamila
, Balde Issa-Bella, Majoul Elyes, Kabiche Sofiane, Bourguignon Elodie, Fontan Jean-Eudes, Cisternino Salvatore, Schlatter Joel
Mar/Apr 2017
Pg. 160-163

The Formulation Development and Stability of Spironolactone Suspension
Alexander Kenneth S
, Vangala Shyam Sundar KS, White Donald B, Dollimore David
May/Jun 1997
Pg. 195-199

The Formulation Development and Stability of Metronidazole Suspension
Alexander Kenneth S
, Vangala Shyam Sundar KS, Dollimore David
May/Jun 1997
Pg. 200-205

Stability of an Oral Liquid Dosage Form of Glycopyrrolate Prepared from Tablets
Gupta Vishnu D
Nov/Dec 2001
Pg. 480-481

Stability of Sotalol Hydrochloride in Extemporaneously Prepared Oral Suspension Formulations
Sidhom Madiha B
, Rivera Nadya, Almoazen Hassan, Taft David R, Kirschenbaum Harold L
Sep/Oct 2005
Pg. 402-406

Recent Formulation Advances and Preparation of Orally Disintegrating Tablets
Ejeta Fikadu
Sep/Oct 2022
Pg. 370-377

Dapsone 2 mg/mL in Ora-Sweet and Ora-Plus
Allen Loyd V Jr
Jan/Feb 2023
Pg. 52

Return to Top